News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChinaBio(R) LLC Releases Week in Review: China Starting Up Revamped IPO System


1/6/2014 9:29:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 4, 2013 --After a 14-month hiatus, China’s IPO window will soon reopen under a new system of more market-oriented procedures, and three life science companies are among the initial 11 IPO candidates; Stellar Biotech of California received $12 million in capital from Amaran, a Taiwanese biotech, as part of a cancer immunotherapy collaboration; DIH Medical, a Beijing-based medical device distributor, gained China rights to market Zynex’s stroke recovery device; Chugai Pharma of Japan will take control of its own China marketing, investing $30 million in a China Medical City facility; China’s disease control agency found that Shenzhen Kangtai Biological’s hepatitis B vaccine did not cause the deaths of nine children; and the CFDA temporarily halted importation of Pfizer’s anti-fungal treatment Diflucan because of missing paperwork. More details….

Stock Symbols: (OTCQB: SBOTF; TSX: KLH) (OTCQB: ZYXI) (JP: 4519) (NYSE: PFE)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES